Navigation Links
CSL Limited Signs Commercial License Agreement with Selexis SA
Date:7/26/2011

GENEVA, July 26, 2011 /PRNewswire/ -- Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL Australia) has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.

"We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform," said Dr. Igor Fisch, CEO, Selexis SA. "This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."  

Terms of the agreement were not disclosed.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

About CSL Limited

Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years of experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2010, the company produced revenues of approximately A$4.5 billion.

For more information visit http://www.csl.com.au  

Media Contact: Robert Meister, (602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. World TB Day Donation Campaign Increases Access to Improved TB Tests in Resource-Limited Settings
2. Healthzone Limited Engages The Trout Group for Investor Relations Services
3. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
4. New President and CEO appointed at Ocean Nutrition Canada Limited
5. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
6. The Independent Committee of the Board of Directors of Tongjitang Appoints Morgan Stanley Asia Limited as Its Financial Advisor
7. Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited
8. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
9. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
10. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
11. Optimization and Scale-up of a Hydrodynamically Limited Anti-Solvent Crystallization Process: From Lab to Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 27, 2016 , ... ... Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice group. ... mechanical and electromechanical patent applications. He has an electrical engineering and computer engineering ...
(Date:4/26/2016)... ... ... The European Patent Office (EPO) today announced that U.S. ... European Inventor Award 2016 in the category "Non-European countries." The winners of the 11th ... Lisbon on June 9th. , The human capacity to walk with fluidity is the ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO ... the first multi-million dollar, multi-year managed services contract in the U.S. intelligence community with ... our leadership team,” said John Younger, founder of Accolo. “We are growing and ...
(Date:4/26/2016)... , ... April 26, 2016 , ... BioFactura, Inc ... Series A round of financing. Healthy investor interest drove significant oversubscription of the ... generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer ...
Breaking Biology Technology:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):